Trial Information

Summary: A clinical study comparing standard treatment for advanced melanoma to an experimental study drug.

Summary:
Pfizer, Inc. is conducting a clinical study to compare overall survival for subjects with advanced melanoma receiving an experimental study drug compared to subjects that receive standard chemotherapy.

Study drug and study procedures will be made available to you at no cost. Procedures that are performed as part of your routine care will be billed to you or your insurance provider.

You may participate in this study if you:

  • Are at least 18 years of age
  • Have advanced melanoma that is not surgically curable
  • Have adequate bone marrow, liver, and kidney function.

You may not participate in this study if you:

  • Have had prior treatment on a clinical trial with the study drug
  • Have any serious uncontrolled medical disorder or infection, or inflammatory bowel disease
  • Have received systemic therapy for your melanoma
  • Have a history of brain cancer.
  • Have a history of hepatitis due to hepatitis B or C
  • Have a history of chronic inflammatory or autoimmune disease
  • Are pregnant or breastfeeding

Contact:

Anna C. Pavlick, DO
Biomedical Research Alliance of New York
NYU Clinical Cancer Center
130 E. 34th Street
New York, NY 10016
Telephone: (212) 263-2171

Profile Page: Biomedical Research Alliance of New York, New York, NY

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: February 25, 2008 at 2:30:32 PM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA